IRCT20230123057193N5 IRCT 2024-10-29 Research assistant of Tehran University of Medical Sciences The effect of L-arginine supplementation on matabolic factors and stress oxidative indices in patients with Metabolic dysfunction-associated steatotic liver disease (MASLD) The effect of L-arginine supplementation on matabolic factors and stress oxidative indices in patients with Metabolic dysfunction-associated steatotic liver disease (MASLD): a double-blind randomized controlled clinical trial 2024-10-22 anticipated 44 Complete https://irct.ir/trial/79312 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: All subjects and researchers and healthcare personnel who are responsible for the care of patients will be unaware of the existing grouping until the end of the study; In such a way, the researcher and the person who takes the sample, like the study participants, are unaware of which patient will receive the vitamin pill or the placebo. Patients are also unaware of the type of pill received. Drugs and placebos are coded by a person who is completely unaware of the study process, and this code is placed in an envelope that indicates whether it is a drug or a placebo code. One group will receive drug A and one group will receive drug B. Also, pills containing L-arginine and placebo, which have the same color, smell, and size as the vitamin pill, will be given to the study subjects every 4 weeks by another person who has no knowledge of the research process. Hence, this study will be a double-blind study. Placebo tablets contain starch and are completely similar to L-arginine tablets in terms of color, appearance and smell. Placebo tablets are also prepared by the same company that manufactures L-arginine, Blinding description: All subjects and researchers will be unaware of the existing grouping until the end of the study, and L-arginine supplement and placebo will be given to subjects once every 4 weeks by another person who has no knowledge of the research process. In order to evaluate the acceptance of the patients, a checklist will be prepared and given to the patients and they will be asked to record their daily consumption in it. In addition, in order to ensure the consumption of supplements, reminder messages will be sent to all patients every da. 2-3 Metabolic dysfunction-associated steatotic liver disease. Intervention 1: Intervention group: Intervention group: The intervention group will receive 3000 mg of arginine daily (3 tablets of 1000 mg) with water for 8 weeks. Arginine tablets are purchased from Karen. All patients will be monitored for pill consumption with a daily checklist and recall messages. Intervention 2: Control group: People in the placebo group will take a pill that is completely similar to the L-arginine supplement in terms of appearance, color and smell, daily in the same way for 8 weeks. Placebo pills are purchased from Karen Company. All patients will be monitored for pill consumption with a daily checklist and recall messages. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is Patient information will remain confidential. There is no further information.